PLP1 and myeloid sarcoma: The finding that most MS patients had isotype-switched anti-PLP181−230 antibodies, whereas those healthy individuals or OND patients with detectable levels of anti-PLP181−230 antibodies generally had antibodies of the IgM isotype, suggests the presence of a PLP-driven immune process occurring in the MS patients.